Search Results

You are looking at 141 - 150 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors: A Plenary Session

Presented by: Kristin Dickinson, Halle C.F. Moore, Jennifer Schmitz, and Eric S. Zhou

Moderated by: Andrew T. Day

to assess and manage in a clinical setting. CRF is often reported to be the most distressing symptom, even more so than pain and nausea.” This is partly because many of the common side effects of cancer and its treatment can be controlled with

Full access

Updates in the Treatment of Metastatic Urothelial Cancer

Presented by: Thomas W. Flaig

.4 months (95% CI, 3.5–7.2 months), a median OS of 10.9 months (95% CI, 9.0–13.8 months), and a response rate of 27%. Treatment-related side effects included hypersensitivity reactions, nausea, vomiting, diarrhea, and bone marrow suppression. Of note, Dr

Full access

NCCN News

for related conditions like nausea, fatigue, distress, or immunotherapy-related toxicities. “The Abramson Cancer Center is a perfect fit and wonderful addition to the group of leading cancer centers that comprise NCCN,” said Robert W. Carlson, MD

Full access

NCCN News

; nausea and vomiting/supportive care; non-Hodgkin's lymphomas; soft tissue sarcoma; and Waldenström's macroglobulinemia. (*Indicates guidelines with recent or upcoming updates.) NCCN Guidelines for Patients and NCCN Quick Guide sheets DO NOT replace the

Full access

NCCN News

different books, including recommendations for breast, colon, lung, and prostate cancers. There are also books on supportive care topics like managing cancer-related distress, nausea and vomiting, side-effects from immune checkpoint inhibitors and CAR T

Full access

NCCN News

than 50 different books for patients and caregivers from NCCN covering every major type of cancer, along with topics like managing cancer-related distress, nausea and vomiting, and special considerations for adolescents and young adults across all

Full access

NCCN News

patients and caregivers covering most major types of cancer, including colon and rectal cancers. There are additional guides covering cancer-related distress, nausea and vomiting, and survivorship (both healthy living and cancer-related late and long

Full access

New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer

Presented by: Gregory J. Riely

, with 11% of patients experiencing grade 3 symptoms and 53% having grade 1 or 2 symptoms. Other common adverse events include nausea, diarrhea, and fatigue. More recently, data on a different BRAF and MEK inhibitor combination, encorafenib

Full access

Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management

Presented by: Gabriela S. Hobbs and Christopher Bell

should result in permanent treatment discontinuation. For severe diarrhea, nausea, or vomiting, supportive care measures should be introduced. If symptoms persist, according to Dr. Bell, the drug should be withheld and may be restarted at a reduced dose

Full access

Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors

Presented by: Rebecca Olin

associated with midostaurin included anemia, rash, and nausea. Figure 1. Intensive induction eligible. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Myeloid Leukemia, Version 4.2023 [AML-1]. ©2023 National Comprehensive